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The amino-terminal region of the humnn sex steroid-binding protein of plasma (SBP or SHBG) containing Kl34 and MI 39 was found to rcprcsent 
part of the steroid-binding site. This was aceomplishcd by constructing and expressing site-directed mutants having the following replacements: 
MI39L, Ml39K. M139S, Kl34A, H235S, and Y57F. The results indicated that Ml39L and H23SS were fuily-active, Kl34A and YS7F wcrc 50 
and G7% active, Ml39K was 7% active, and M 139s was inactive. These results upport affinity-labeling data indicating that both K134 and Ml39 
are located in or near the site, and suggest that Y57 may play a role in skroid binding. The fully active H23SS mutant reveals thnt H235 is not 
involved in the steroid-binding process. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
The human sex steroid-binding protein, SBP (or sex 
hormone binding globulin, SHBG) is a 93.4 kDa ho- 
modimeric glycoprotein that specifically binds testoster- 
one (T) and 17/?-estradiol (EJ with high affinity in 
plasma, controls their metabolic clearance rates, and 
has been implicated in the endocytosis of sex steroid 
hormones into target cells (see [l] for a review). The 
human and rabbit proteins have been extensively char- 
acterized [2] and their amino acid sequences were deter- 
mined [3,4]. The human SBP sequence agrees with that 
deduced from a full-length cDNA constructed from 
PCR fragments 11 ,S]. The oligosaccharide side-chains of 
hSBP are linked to T7, N351, and N367, and were 
found to play no role in steroid binding [6]. Human SBP 
has been expressed in BHK-21 and COS-7 cells [S] and 
in CHO cells [7]. This laboratory is interested in devel- 
oping SBP as a protein model to understand the molec- 
ular basis of protein-steroid binding and the role of the 
protein in sex steroid hormone transport. Recently, the 
steroid-binding site of the human protein was tenta- 
tively identified in the region incorporating residues 
K 134 and M 139, as determined by affinity labeling with 
Sa-dihydrotestosterone d rivatives [8,9]. In order to 
confirm this result, as well as testing other residues im- 
plicated in the steroid-binding process, we have mutated 
IC134, Ml 39, and other residues, and related the conse- 
quence of their replacements o the steroid-binding ac- 
tivity of the expressed mutated recombinant proteins. 
A full-length hSBP cDNA was cloned in pBlueseript II SK (Sttat- 
agcne) as previously dcacribed [!I]. Site-directed mutagenesis was ear- 
ricd Ott1 according to Kunkel et al. [IO] using the Version 2 Muta-Gene 
Phagcmid kit (Bio-Rad) with antisense mutated oligonucleotides syn- 
thcsizcd on an Applied Biosystems model 3LOA DNA synthesizer. 
Mutated cDNAs were subclond into peDNA/Neo (Invitrogen) as 
previously described [S] and sites of mutations were confirmed by 
double-stranded DNA sequencing using the Sanger method [II]. 
Transfcetions of mulaled peDNAY NeolSBPand wild.typc into COS- 
7 cells were mediated by DEAE-dcxtran [I21 along with control trans- 
feclions with pcDNAIMeo. Cells were grown in DMEM medium 
containing 5% calf serum. Media from transf=ted eells were eollectcd 
B days after transfcction and nssayed by ELISA [I31 and charcoal 
adsorption. The latter was earricd out by incubating samples with a 
3-4fold molar excess of ['H]DHT over SBP (& a IOO-fold molar excess 
of radio-inert DHT) for 20 min at 25°C and IO min in ice. The samples 
were added to a charcoal pellet prepared from a standard solution 
(0.5% Norit A, O.OS% dextran T-70,0.1 % gelatin) using twiec the SBP 
sample volume. The mixture was mixed, left on ice for 10 mitt, and 
spun ror 2 min al 14,ooO rpm. Competilion stud& were ear&l out 
by incubating the medium with IO nM [‘H]Sa-DHT (Sh-dlhydro- 
testosterone) and a IOO-fold molar excess of radio-inert DHT. T, Ez 
(lirp-estradiol). P (progesterone), and F (cortisol). 
3. RESULTS AND DISCUSSION 
Currespondeme adf~css: P.H. Peva, Department of Obstetrics and 
Gynecology, University of Washington, Seattle. WA 9819.5, USA. 
Fax: (I) (206) 543-4365. 
The experiments presented here were designed to test 
whether or not K134, M139, H235 and Y57 play a role 
in the steroid-binding activity of SBP. A total of seven 
mutants were constructed and expressed: M139L, 
M139K, Ml39S, M139D, K134A, H235S, and Y57F. 
Fig. 1 shows portions of the DNA sequencing els cod- 
ing for the K134A and M 1395 replacements, along with 
the sequence of wild-type SBP encompassing these two 
residues. All other gels demonstrated that the proper 
mutations had been made (data not shown). Since pro- 
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tein stability is related to tight ‘packing of amino acid 
side chains within the interior of proteins, where, in the 
case of SBP, the steroid-binding site is likely to be 
located, we chose to mutate with residues similar or 
smaller than the wild-type to minimize perturbation in 
internal packing which could result in loss of activity 
through undesirable conformation changes. The empty 
space arising from replacing with smaller residues 
would be expected to be filled through slight movements 
of surrounding side chains thus decreasing the chance 
of producing large non-specific onformation changes. 
Loss of activity in such cases is therefore more likely to 
reflect a loss of unction by the elimination of a steroid- 
binding group. The M139L replacement matches as 
closely as possible the structure of methionine whereas 
those in the Ml39S, Ml39K, and M139D mutants de- 
pict changes in size and hydrophobicity. Removal of 
most of the lysine side chain in the Kl34A mutant and 
the imidazole ring in the H235S mutant were carried out 
to test the role of these residues previously implicated 
in steroid-binding [9,14]. Also included was a Y57F 
mutant o test a possible role for the sole phenolic group 
in SBP. Table I shows that major changes in the struc- 
ture of the Ml 39 side chain reduce the specific DHT- 
binding activity. As expected, a change to leucine has 
little effect on the activity, suggesting that a certain 
freedom of movement of the methionine side chain can 
Wild Type I 
I-A’\ 
be tolerated within the binding site. However, any de- 
crease in size or hydrophobicity, as indicated by the 
serine and lysine replacements, produces a major reduc- 
tion in activity. Also, elimination of most of the lysine 
side chain of ICI 34 and the phenolic group of YS7 re- 
duces the activity. The M139D mutant could not be 
tested because its expression in COS-7 cells was ex- 
tremely low even after repeated transfections. Table I 
and the Scatchard plots in Fig. 2 also reveal that the 
apparent &s for both Ml 39L and H235S are similar to 
wild-type SBP, while those for M 139K, M 139S, K134A, 
and Y57F mutants are markedly higher, as predicted 
from the specific activities hown in the Table. Since the 
rates of DHT dissociation for the M139K, Ml39S, 
Kl34A, and Y57F mutants are unknown, we must em- 
phasize that the values of these &s may not reflect a 
true measure of the dissociation constants since the 
equilibrium concentration of bound DHT could have 
changed uring the measurement if the rates of dissoci- 
ation were high. Nonetheless, they are markedly differ- 
ent from those of the Ml39L and H23SS mutants which 
bind DHT with the same affinity as the wild-type. The 
results therefore strongly indi,cate that the Ml39 side- 
chain contributes ignificant energy of binding to the 
steroid and thus resides within the binding site. We offer 
the following explanation for the activity loss of the 
M139K and M139S mutants: presence of the positive 
M134A I 
T Q!4! 
,T J 
?jl!el”’ 
Fig. 1. DNA sequencing gels indiouing portions ofthe SBP sequence incorporating K134 and M139. The arrows point to mutated nucleotides 
coding for the indicated amino acid , ~~~~lascments, 
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Table I 
Steroid-binding properties and levels of wild-type and mutated SBPs secreted by transfccted CDS-7 cells 
DHT binding 
(nM1 
EL&A 
(nM1 
Specific aclivity 
(DHT bindin@ELISA) (k, 
pcDNAI/Neo (control, no SBP) G.30” Ob 0.76’ 
pcDNAIMeo/SBP (wild-type) I.86 2.48 00.75 (loo%) 0.68 
M139L 2.04 2.91 0.70 (93%) 0.74 
M139K 0.1 I 2.35 0.0s (7%) 2.30 
M139S 0 1.16 0 (0%) l.IQ 
Kl34A I .28 3.39 0.38 (50%) 2.11 
H235S 2.32 2.68 0.87 (I 16%) 0.85 
YS7F 1.40 2.80 0.50 (ti78) 2.00 
“These values rcprescnt specific binding measured by the charcoal assay at ligand saluration. Each value was corroctcd for non-spceific binding 
by using a 100.fold molar excess of mdio-inert DHT. 
“This amount of DHT binding activity corresponds tothe low concentrations of calf SBP in the culture medium (5% calfserum). The ELISA cannot 
detect calf SBP because the polyclonal antibodies raised against hSBP do not cross-rcacl with it [l6]. That amount of DHT binding activity was 
subtracted from all the values in the Table. 
c The total DHT-binding activity of the Ml39S mutant was equal to that measured inthe cullurc medium containing COS-7 cells transtitctcd with 
control pcDNAl/Nco. These values thcrcforc orrespond to the K,, OT calf SBP. The variation is within experimental errors. 
charge in the former inhibits steroid biading due to 
repulsion by the positive charge of Kl39, while removal 
of the methyl and sulfur groups in the latter reduces 
hydrophobicity and may result in the partial collapse of 
the binding site. A recent report indicates that a M I39W 
SBP mutant has a lower steroid-binding affinitj; than 
wild-type SBP [IS]. Although that observation agrees 
with the conclusions presented here, one sole replace- 
ment by a larger residue, such as tryptophan, is difficult 
to interpret in terms of a structure-function relationship 
for the reasons tated above. Although a large confor- 
mation change may not necessarily occur in this case, 
the significant structural change at the immediate site 
of replacement is likely to be too drastic to interpret he 
resulting loss of activity solely on the basis of the elim- 
ination of the methionine side chain. Other replace- 
ments, particularly by smaller residues as done here, 
must be carried out before a conclusion can be made. 
Lastly, competition experiments with T, E?, P, and F 
show that the active mutants have the same steroid- 
binding specificities as wild-type SBP (data not shown). 
As shown in Table I and Fig. 2, expression of the 
Kl34A mutant, lacking most of the lysine side chain, 
produced a recombinant SBP that had lost about 50% 
of its DMT-binding activity and had a higher apparent 
&. Due to its proximity to Ml39, removal of the Kl34 
side chain probably induced a conformation change in 
the steroid-binding site through the elimination of a 
stabilizing salt-bridge, as proposed recently [1,9]. In 
order to explain the complete loss of activity obtained 
in. the specific alkylation of K134 by the affinity label, 
17~-[([2-‘~C]bromoacety1)oxy]-5a-androstan-3-one [9], 
we propose that reaction by the bromomethyl ketone 
group of the label took place by extending to the outside 
of the site, about 6-8 A from the C-l 7 of the steroid (the 
approximate l ngth of the bromomethyl ketone group) 
where K134 is probably located. Covalent attachment 
of the label to K134 must have caused inactivation by 
blocking the site, thus preventing [‘HjDHT from bind- 
ing during the assay. We conclude that K134 is proba- 
bly located at the entrance of the site and is unlikely to 
contact he steroid as proposed earlier [1,9]. 
Mutation at H235 was carried out to resolve the exist- 
ing controversy of whether or not this residue is present 
in the steroid-binding site [9,14]. Expression of a H235S 
mutant yielded a fully active recombinant protein, indi- 
cating that the imidazole ring of H235 is not present in 
the steroid-binding site or involved in stabilizing the 
0 1 
Bound (nM) 
Fig. 2. Estimation of the equilibrium constants of dissociation of 
wild-type and mutant SBR seemted by COS-7 cells using the chnrcoal 
mrlhod described in the 1~x1. The inset rcpresenls plots for the Ml39K 
and -Mi39S mulblnis wiib cnpaukd soak. (Cj Wikkyp; (G;;) fi%% 
(0) Ml39L; (0) Kl34A; (e) Y57F; (A) Ml39K; (A) M139S. Theab- 
scissa intercept for the Ml39L mutant is slightly greater than the 
wild-type. The Kds calculated from these plots 31x listed in Table I. 
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site. In fact, the earlier claim for the alkylation of H235 
by 1 7,&[([2-1’C]bromoacetyl)oxy]-5a-androstan-3-one 
was based on insufficient data (10 dpm over back- 
ground, Table I of [14]). Removal of the phenolic group 
of Y57 lowers the activity, suggesting a possible role for 
this group in the steroid-binding activity, and indicating 
that the amino-terminal region of SBP containing Y57 
may fold near the steroid-binding site. Other replace- 
ments at or near Y57 must be carried out to clarify the 
role of this residue in the steroid-binding process. In 
conclusion, the amino-terminal region containing K; 34 
and Ml39 residues represents part of the steroid-bind- 
ing site of human SBP. Other experiments are now in 
progress to expand on these observations with the uhi- 
mate goal of identifying all the residues involved in the 
steroid-binding process. 
REFERENCES 
[I] Petra, P.H. (1991) J. Steroid Biochem. Mol. Biol. 40, 735-753. 
[2] Petra, P.M., Namkung, PC., Senear. D.F., McCrac, D.A., 
Rousslang, K.W., Tcllcr, D.C. and ROSS, J.B.A. (1986) J. Ster. 
Biochem. 25, 191-200. 
[3] Walsh, K.A., Titani, K., Kumar, S., Hayes, R. and Petra, P.H. 
(1986) Biochemistry 25, 7584-7590. 
141 
151 
[~I 
[71 
PI 
t91 
t101 
u 11 
1121 
1131 
1141 
D51 
WI 
Griffin, P.R., Kumar, S., Shabanowitz, J., Charbonneau, Ii., 
Namkung, P.C.. Walsh. K.A., Hunt, D.F. and P&a, P.M. (1989) 
1. Biol. Chcm. 264, 19066-19075. 
Hagen, FS,, ArguelIes, C., Sui, L.M., Zhang, W., Seidcl, P.R., 
Conroy, S.C. and Pctra, P.M. (1992) FEBS Lett. 299, 23-27. 
Petra, P.H., Griffin, P.R., Yates 111, J R., Moore, K. and Zhang, 
W. (1992) Protein Sci,‘(in press). 
Elocchinfuso, W.P., Warm&-Rodenhiser, S. and Hammond, 
G.L. (1991) Mol. Endocrinol, 5, 1723-1729. 
Grenot, C., Montard, A., Blachere, T., Mappus. E. and Cuil- 
leron, C.Y. (1988) CR. Acad. Sci. Paris, t. 307, Serie III, p, 
391-396. 
Namkung, PC.. Kumar, S., Walsh, K.A. and Petrs, P.H. (1990) 
J. Biol. Chcm. 265, 18345-18350. 
Kunkel, T.A., Roberts, J.D. and Zakour, R.A. (1987” Methods 
Enzymol. 154, 367-382. 
Sanger, F., Nicklcn, 5. and Coulson, A.R. (1977) Proc. Natl. 
Acad. Sci. USA 74,5463-5467. 
Ausubcl, F.M., Brent, R. and Kingston, R.E. ct al. (1990) in: 
Current Protocols in Molecular Biology, vol. 1, pp. 9.21-9.23, 
Wiley-Interscience, NY. 
Bordin, S., Torres, R. und Pelro, P.H. (1982) J. Steroid Biochem. 
17,453-457. 
Khan, MS and Roster, W. (1990) J. Diol. Chem. 265. 8431- 
8435. 
Bocchinfuso, W.P., Warmels-Rodenhiser, S. and Hammond. 
G.L. (1992) FEBS Lutt. 301,227-230. 
Petra, P.H. (1979) 5. Steroid Biochem. II, UT-X?. 
118 
